公开(公告)号：EP1474425B1

公开(公告)日：2006-05-24

申请号：EP03729359.4

申请日：2003-01-07

申请人： Eisai Co., Ltd.

发明人： DAUN, Jane ,  DAVIS, Heather, A. ,  GUSOVSKY, Fabian ,  HISHINUMA, Ieharu ,  JIANG, Yimin ,  KANEKO, Toshihiko ,  KIKUCHI, Kouichi ,  KOBAYASHI, Seiichi ,  LESCARBEAU, Andre ,  LI, Xiang-Yi ,  MURAMOTO, Kenzo ,  OHI, Norihito ,  PESANT, Marc ,  SELETSKY, Boris, M. ,  SOEJIMA, Motohiro ,  YAO, Ye ,  YOKOHAMA, Hiromitsu ,  ZHAO, Yan, J. ,  ZHENG, Wanjun ,  TREMBLAY, Lynda ,  DeCOSTA, Bruce F. ,  SPYVEE, Mark

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P31/12 ,  A61P35/00 ,  A61P37/00 ,  A61P29/00

CPC分类号： A61K31/437 ,  C07D471/04

摘要： The present invention provides compounds having formula (I), wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.

公开(公告)号：EP1474425B9

公开(公告)日：2008-07-02

申请号：EP03729359.4

申请日：2003-01-07

申请人： Eisai Co., Ltd.

发明人： DAUN, Jane ,  DAVIS, Heather, A. ,  GUSOVSKY, Fabian ,  HISHINUMA, Ieharu ,  JIANG, Yimin ,  KANEKO, Toshihiko ,  KIKUCHI, Kouichi ,  KOBAYASHI, Seiichi ,  LESCARBEAU, Andre ,  LI, Xiang-Yi ,  MURAMOTO, Kenzo ,  OHI, Norihito ,  PESANT, Marc ,  SELETSKY, Boris, M. ,  SOEJIMA, Motohiro ,  YAO, Ye ,  YOKOHAMA, Hiromitsu ,  ZHAO, Yan, J. ,  ZHENG, Wanjun ,  TREMBLAY, Lynda ,  DeCOSTA, Bruce F. ,  SPYVEE, Mark

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P31/12 ,  A61P35/00 ,  A61P37/00 ,  A61P29/00

CPC分类号： A61K31/437 ,  C07D471/04

公开(公告)号：EP1463719A2

公开(公告)日：2004-10-06

申请号：EP03715921.7

申请日：2003-01-08

申请人： Eisai Co., Ltd

发明人： AGOULNIK, Sergei ,  AKASAKA, Kozo ,  FANG, Frank ,  HARMANGE, Jean-Christophe ,  HAWKINS, Lynn ,  JIANG, Yimin ,  JOHANNES, Charles ,  LI, Xiang-Yi ,  MCGUINNESS, Pamela ,  MURPHY, Erin, A. ,  SCHILLER, Shawn ,  VERMEULEN, Mary ,  WU, Jiayi

IPC分类号： C07D303/36 ,  C07D405/12 ,  C07D407/12 ,  C07D209/48 ,  A61K31/336 ,  A61K31/16 ,  A61K38/05 ,  A61P35/00 ,  A61P29/00 ,  C07K5/06 ,  C07C235/08 ,  C07C235/06 ,  C07C233/76 ,  C07C235/82 ,  C07C271/22 ,  C07F5/02 ,  C07F9/655 ,  A61K31/665 ,  A61K31/69

CPC分类号： C07D209/48 ,  A61K38/00 ,  C07D303/36 ,  C07D405/12 ,  C07D407/12 ,  C07F5/025 ,  C07F9/65502 ,  C07K5/06139

摘要： The present invention provides compounds having formula (I) : wherein R1-R6, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

公开(公告)号：EP1507773A1

公开(公告)日：2005-02-23

申请号：EP03721353.5

申请日：2003-03-07

申请人： Eisai Co., Ltd

发明人： BOIVIN, Roch ,  CHIBA, Kenichi ,  MURAMOTO, Kenzo ,  SHIROTA, Hiroshi ,  DU, Hong ,  EGUCHI, Yoshihito ,  FUJITA, Masanori ,  GUSOVSKY, Fabian ,  GOTO, Masaki ,  HARMANGE, Jean-Christophe ,  INOUE, Atsushi ,  JIANG, Yimin ,  KAWADA, Megumi ,  KAWAI, Takatoshi ,  KAWAKAMI, Yoshiyuki ,  KIMURA, Akifumi ,  KOTAKE, Makoto ,  KUBOI, Yoshikazu ,  LEMELIN, Charles-André ,  LI, Xiang-Yi ,  MATSUSHIMA, Tomohiro ,  MIZUI, Yoshiharu ,  SAKURAI, Hideki ,  CHOW, Jesse ,  SHEN, Yong-Chun ,  SPYVEE, Mark ,  TANAKA, Isao ,  WANG, John (Yuan) ,  YAMAMOTO, Satoshi ,  YONEDA, Naoki ,  KOBAYASHI, Seiichi

IPC分类号： C07D313/00 ,  A61K31/335 ,  A61P29/00 ,  C07D225/06 ,  C07D407/12 ,  C07D491/04 ,  C07D267/00 ,  C07D493/04 ,  A61K31/36 ,  A61K31/395 ,  A61P11/06 ,  A61P17/06 ,  A61P17/16 ,  A61P19/04 ,  A61P35/00 ,  A61P37/06

CPC分类号： C07D405/12 ,  A61K31/335 ,  A61K31/36 ,  A61K31/395 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D313/00 ,  C07D401/12 ,  C07D491/04 ,  C07D491/044 ,  C07D493/04 ,  Y02A50/411

摘要： The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R 1 -R 11 , t, X, Y, Z and n are as defined herein.